Primary medical focus of the company is arthritis, fibrotic diseases, and skin regeneration.

CarthroniX is in the process of IND filing for a Phase 1-2A human clinical trial of our lead molecule in patients with osteoarthritis of knee. This trial will begin in Q3 2024. Our current drug development pipeline also includes promising small molecules and revolutionary therapeutic peptides for fibrotic disorders. CarthroniX is also conducting exploratory research to determine the utility of the novel gp130 modulators for metastatic cancer and idiopathic pulmonary fibrosis (IPF).